Get startedLog in
    Picture of enGene Therapeutics logo

    ENGN — enGene Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapNeutral
    All News

    enGene Holdings Inc expected to post a loss of 50 cents a share - Earnings Preview

    Picture of enGene Therapeutics logoenGene Therapeutics
    09/06/2025 04:02
    enGene Holdings Inc ENGN.OQ ENGN.O is expected to show no change in quarterly revenue when it reports  results on June 11 (estimated) for the period ending April 30 2025

​LSEG's mean analyst estimate for enGene Holdings Inc is for a loss of 50 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for enGene Holdings Inc is $25.00​, above​ its last closing price of $3.78. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​


    QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
    Jan. 31 2025-0.36-0.37-0.48Missed-29.3
    Oct. 31 2025-0.39-0.38-0.34Beat10
    Jul. 31 2024-0.43-0.37-0.32Beat14.7​
    Apr. 30 2024-0.26-0.26-0.38Missed-45
    ​​
    ​
    

This summary was machine generated June 9 at 03:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

    Recent news on enGene Therapeutics

    See all news